Prostate cancer is the second most common cancer among men, with approximately 1,276,106 new cases per year worldwide. About six out of 10 cases are diagnosed in men 65 years of age or older. Despite its high incidence, there is currently no routine prostate cancer screening program for the general population. Currently, the main tools for tracking this pathology are digital rectal examination, serum concentration of Specific Prostatic Antigen (PSA) and transrectal ultrasound. PSA, a protein synthesized almost exclusively by prostate epithelial cells, is the most used marker and, although, it is an organ-specific protein,since its contentration can be increased by the incidence of other diseases, such as benign prostatic hyperplasia or prostatitis. Thus, the quantification of PSA does not allow to distinguish between possible benign conditions of the prostate and prostate cancer, presenting a low specificity. Therefore, it is important to have a screening procedure capable of verifying the risk of aggression of the pathology, at first, without the need to perform the biopsy.
The Stockholm3 test is a non-invasive screening analysis for aggressive prostate cancer (defined as ISUP> 2) in men aged 50-69 years. The test determines the concentration of five plasma markers in a blood sample (PSA, free PSA, hK2, MSMB and MIC1), as well as the analysis of 101 genetic variants. The results of the analysis are integrated into an algorithm that includes the patient’s age, family history and the result of the previous biopsy, if any. Due to the integration of the different parameters, it is possible to define a risk percentage (score risk) that the prostate biopsy is positive if performed (Gleason ≥7). Scientific studies show that the application of this test can reduce the number of biopsies by 32%, without compromising the diagnostic capacity of medium grade prostate cancers (Gleason ≤7), in comparison with the use of the PSA value 3 ng / mL as cut-off value for biopsy recommendation. The Stockholm3 test provides information relevant to making decisions about performing a biopsy.
It is indicated for men of 50-69 years with:
• Family history of prostate cancer
• High PSA (> 1.5 ng / mL) or anomalous rectal touch
• Negative result in a previous biopsy
Biochemical and Genetic Analysis
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Minimally invasive analysis
• Reduces the initial need to perform a biopsy
• Increase the detection rate of aggressive cancers compared to current clinical practice.
• Allows to detect aggressive cancer in humans with low PSA values (1.5-3 ng / mL).
• Disminuye the number of unnecessary biopsies in a 50% compared to the usual clinical practice.
• Provides concise recommendations based on risk, facilitating the specialist to make decisions and reduce waiting times between the initial task and the first treatment.
Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• It is not necessary fasting for the test.
• Do not perform in case of: previous diagnosis of prostate cancer; performing a prostate biopsy during the 2 weeks prior to sample collection.